A quality initiative focused on BRCA and HRD testing and use of first line maintenance in advanced ovarian cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This ...

Over 20% of high-grade serous ovarian cancer patients have BRCA mutations, and up to 50% exhibit HRD, impacting DNA repair pathways. Global guidelines recommend BRCA and HRD testing, but many eligible ...

Integrating new AI screening tools for BRCA and HRD breast-cancer mutations into routine care could lead to earlier detection, more precise treatment, and lives saved. If they are aware of the threat, ...

Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, ...

Starting in 2014, poly (ADP-ribose) polymerase inhibitors (PARPi) have been approved for the treatment of BRCA-mutated (BRCAm) and/or homologous recombination deficiency (HRD)-positive ovarian cancer, ...

The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...

BARCELONA, Spain & MONTPELLIER, France--(BUSINESS WIRE)--SeqOne, provider of new generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD ...

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among ...

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at ...